These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 38276234)

  • 1. Parkinson's Disease and Photobiomodulation: Potential for Treatment.
    Bicknell B; Liebert A; Herkes G
    J Pers Med; 2024 Jan; 14(1):. PubMed ID: 38276234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Remote Photobiomodulation Treatment for the Clinical Signs of Parkinson's Disease: A Case Series Conducted During COVID-19.
    Liebert A; Bicknell B; Laakso EL; Jalilitabaei P; Tilley S; Kiat H; Mitrofanis J
    Photobiomodul Photomed Laser Surg; 2022 Feb; 40(2):112-122. PubMed ID: 34919459
    [No Abstract]   [Full Text] [Related]  

  • 3. Photobiomodulation for Parkinson's Disease in Animal Models: A Systematic Review.
    Salehpour F; Hamblin MR
    Biomolecules; 2020 Apr; 10(4):. PubMed ID: 32326425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improvements in clinical signs of Parkinson's disease using photobiomodulation: a prospective proof-of-concept study.
    Liebert A; Bicknell B; Laakso EL; Heller G; Jalilitabaei P; Tilley S; Mitrofanis J; Kiat H
    BMC Neurol; 2021 Jul; 21(1):256. PubMed ID: 34215216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pre-conditioning with Remote Photobiomodulation Modulates the Brain Transcriptome and Protects Against MPTP Insult in Mice.
    Ganeshan V; Skladnev NV; Kim JY; Mitrofanis J; Stone J; Johnstone DM
    Neuroscience; 2019 Feb; 400():85-97. PubMed ID: 30625333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disease-modifying treatment of Parkinson's disease by phytochemicals: targeting multiple pathogenic factors.
    Naoi M; Maruyama W; Shamoto-Nagai M
    J Neural Transm (Vienna); 2022 Jun; 129(5-6):737-753. PubMed ID: 34654977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Remote photobiomodulation targeted at the abdomen or legs provides effective neuroprotection against parkinsonian MPTP insult.
    Gordon LC; Martin KL; Torres N; Benabid AL; Mitrofanis J; Stone J; Moro C; Johnstone DM
    Eur J Neurosci; 2023 May; 57(9):1611-1624. PubMed ID: 36949610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Parkinson's disease: Autoimmunity and neuroinflammation.
    De Virgilio A; Greco A; Fabbrini G; Inghilleri M; Rizzo MI; Gallo A; Conte M; Rosato C; Ciniglio Appiani M; de Vincentiis M
    Autoimmun Rev; 2016 Oct; 15(10):1005-11. PubMed ID: 27497913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mitochondrial Dysfunction and Parkinson's Disease-Near-Infrared Photobiomodulation as a Potential Therapeutic Strategy.
    Foo ASC; Soong TW; Yeo TT; Lim KL
    Front Aging Neurosci; 2020; 12():89. PubMed ID: 32308618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Photobiomodulation in Rescuing Lipopolysaccharide-Induced Dopaminergic Cell Loss in the Male Sprague-Dawley Rat.
    O'Brien JA; Austin PJ
    Biomolecules; 2019 Aug; 9(8):. PubMed ID: 31430990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of Neurodegeneration: Integrating Photobiomodulation and Neurofeedback in Alzheimer's Dementia and Parkinson's: A Review.
    Berman MH; Nichols TW
    Photobiomodul Photomed Laser Surg; 2019 Oct; 37(10):623-634. PubMed ID: 31647776
    [No Abstract]   [Full Text] [Related]  

  • 12. A novel transcranial photobiomodulation device to address motor signs of Parkinson's disease: a parallel randomised feasibility study.
    Herkes G; McGee C; Liebert A; Bicknell B; Isaac V; Kiat H; McLachlan CS
    EClinicalMedicine; 2023 Dec; 66():102338. PubMed ID: 38094162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amelioration of Motor Performance and Nigrostriatal Dopamine Cell Volume Using a Novel Far-Infrared Ceramic Blanket in an A53T Alpha-Synuclein Transgenic Parkinson's Disease Mouse Model.
    Carrick FR; Hernandez LSAV; Sugaya K
    Curr Issues Mol Biol; 2023 Dec; 45(12):9823-9837. PubMed ID: 38132459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rasagiline and selegiline modulate mitochondrial homeostasis, intervene apoptosis system and mitigate α-synuclein cytotoxicity in disease-modifying therapy for Parkinson's disease.
    Naoi M; Maruyama W; Shamoto-Nagai M
    J Neural Transm (Vienna); 2020 Feb; 127(2):131-147. PubMed ID: 31993732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic, low-dose rotenone reproduces Lewy neurites found in early stages of Parkinson's disease, reduces mitochondrial movement and slowly kills differentiated SH-SY5Y neural cells.
    Borland MK; Trimmer PA; Rubinstein JD; Keeney PM; Mohanakumar K; Liu L; Bennett JP
    Mol Neurodegener; 2008 Dec; 3():21. PubMed ID: 19114014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation.
    Tong J; Wong H; Guttman M; Ang LC; Forno LS; Shimadzu M; Rajput AH; Muenter MD; Kish SJ; Hornykiewicz O; Furukawa Y
    Brain; 2010 Jan; 133(Pt 1):172-88. PubMed ID: 19903734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implications of the Gut Microbiome in Parkinson's Disease.
    Elfil M; Kamel S; Kandil M; Koo BB; Schaefer SM
    Mov Disord; 2020 Jun; 35(6):921-933. PubMed ID: 32092186
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular Communication Between Neuronal Networks and Intestinal Epithelial Cells in Gut Inflammation and Parkinson's Disease.
    Drobny A; Ngo PA; Neurath MF; Zunke F; López-Posadas R
    Front Med (Lausanne); 2021; 8():655123. PubMed ID: 34368179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Mechanisms by Which the Ketone Body D-β-Hydroxybutyrate May Improve the Multiple Cellular Pathologies of Parkinson's Disease.
    Norwitz NG; Hu MT; Clarke K
    Front Nutr; 2019; 6():63. PubMed ID: 31139630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
    Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
    Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.